18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma

Stopped early · Phase 2

Conditions studied: Recurrent Adult Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma

In brief

This phase II trial is studying 18F-fluoromisonidazole and fludeoxyglucose F 18 PET/CT scans to see how well they work in assessing oxygen in tumor tissue of patients with soft tissue sarcoma undergoing chemotherapy with or without radiation therapy. Using diagnostic procedures, such as 18F-fluoromisonidazole and fludeoxyglucose F 18 PET scan and CT scan, to find oxygen in tumor cells may help in planning cancer treatment. It may also help doctors predict how well a patient will respond to treatment.

Key facts

Study ID

NCT01169350

Run by

National Cancer Institute (NCI)

People needed

8

Starts

2010-02-01

Expected to finish

2013-08-01

Last updated by the study team

2017-11-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed intermediate- or high-grade soft tissue sarcoma
• Biopsy proven or highly suspicious primary or recurrent disease
• Tumor size ≥ 2 cm
• Scheduled to undergo neoadjuvant chemotherapy with or without radiotherapy
• Life expectancy ≥ 12 months
• Negative pregnancy test
• Willing to undergo PET scanning
• Willing to undergo possible urinary bladder catheterization (for patients with pelvic or proximal thigh tumors)
• Able to lie on the imaging table for up to 1.5 hours
• Weight ≤ 400 lbs
• Not pregnant

Where it is running

• Seattle Cancer Care Alliance — Seattle, Washington, United States
• University of Washington Medical Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.